Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vivos Therapeutics, Inc.VVOS · Entity 8396 | Principal Accounting Officer | July 31, 2026 | August 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vivos Therapeutics, Inc.
Report date July 31, 2026 · Filed August 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 250,080 |
Reported balance
After 2026-07-31 transaction · row 1
1 source rowRow 1 · 2026-07-31 · Grant · Acquired 250,000 · Balance 250,080 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.41 · Expires 2036-07-31 | Direct | 326,533 |
Reported balance
After 2026-07-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-31 · Grant · Acquired 150,000 · Balance 326,533 F1: On July 31, 2026 (the "Grant Date"), the Reporting Person received a grant of 150,000 stock options, which grant was made under the Issuer's 2024 Omnibus Equity Incentive Plan. Stock options shall vest and become exercisable at the rate of 25,000 shares per month from November 1, 2026 through April 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 31, 2026 (the "Grant Date"), the Reporting Person received a grant of 150,000 stock options, which grant was made under the Issuer's 2024 Omnibus Equity Incentive Plan. Stock options shall vest and become exercisable at the rate of 25,000 shares per month from November 1, 2026 through April 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Aug 26, 2026 20:10 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.41 Strike: $0.41 | $61,500.00 |
DisclosureSEC source: 0001493152-26-040238 · ownership.xml · derivative · entry 2 Amman Bradford K. · CIK 0001425339 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 326,533 Underlying: Common Stock · 150,000 shares Expires 2036-07-31 F1 · derivative.exercise_date: On July 31, 2026 (the "Grant Date"), the Reporting Person received a grant of 150,000 stock options, which grant was made under the Issuer's 2024 Omnibus Equity Incentive Plan. Stock options shall vest and become exercisable at the rate of 25,000 shares per month from November 1, 2026 through April 1, 2026. Read SEC document |
| July 31, 2026 Filed Aug 26, 2026 20:10 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantCommon Stock | 250,000 | $0.41 | $102,500.00 |
DisclosureSEC source: 0001493152-26-040238 · ownership.xml · nonDerivative · entry 1 Amman Bradford K. · CIK 0001425339 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,080 Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 21:43 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 149,533 | $2.64 Strike: $2.64 | $394,767.12 |
DisclosureSEC source: 0001493152-24-048023 · ownership.xml · derivative · entry 2 Amman Bradford K. · CIK 0001425339 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,533 Underlying: Common Stock · 149,533 shares Expires 2034-09-07 F1 · derivative.exercise_date: On September 7, 2024 (the "Grant Date"), the Reporting Person received a grant of 180,533 stock options, which grant was made under but subject to stockholder approval of the Issuer's 2024 Omnibus Equity Incentive Plan and such grant at the Issuer's 2024 Annual Meeting. Such meeting was held, and such stockholder approval was obtained, on November 26, 2024. Stock options shall vest and become exercisable in three installments subject to achievement of the following three performance metrics: (1) quarter over quarter revenue growth of at least 15% over the same prior year quarter, (2) total stockholder return from date of grant, and (3) positive cash flow for two consecutive quarters. Read SEC document |
| June 20, 2024 Filed Jun 29, 2024 00:53 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $2.38 Strike: $2.38 | $35,700.00 |
DisclosureSEC source: 0001493152-24-025686 · ownership.xml · derivative · entry 2 Amman Bradford K. · CIK 0001425339 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,667 Underlying: Common Stock · 15,000 shares Expires 2029-06-20 F1 · derivative.exercise_date: On June 20, 2024 (the "Grant Date"), the Reporting Person received a grant of 15,000 stock options from the Issuer. One-fifth vested immediately and one-fifth will vest annually on each anniversary of the Grant Date through June 20, 2028. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 02:45 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.48 Strike: $0.48 | $96,000.00 |
DisclosureSEC source: 0001493152-22-036726 · ownership.xml · derivative · entry 1 Amman Bradford K. · CIK 0001425339 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,001 Underlying: Common Stock · 500,001 shares Expires 2027-12-23 F1 · derivative.exercise_date: 200,000 stock options granted on December 23, 2022. One-fifth vests annually on each anniversary date through December 23, 2026. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 23:50 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $3.27 Strike: $3.27 | $163,500.00 |
DisclosureSEC source: 0001493152-22-005660 · ownership.xml · derivative · entry 1 Amman Bradford K. · CIK 0001425339 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-02-25 F1 · derivative.exercise_date: 50,000 stock options granted on February 25, 2022. One-fifth vested immediately and one-fifth vests annually on each anniversary date through February 25, 2026. Read SEC document |
| August 31, 2021 Filed Sep 3, 2021 01:27 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $5.26 Strike: $5.26 | $263,000.00 |
DisclosureSEC source: 0001493152-21-021915 · ownership.xml · derivative · entry 2 Amman Bradford K. · CIK 0001425339 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-08-31 F1 · derivative.exercise_date: 50,000 stock options granted on August 31, 2021. One-fifth vested immediately and one-fifth vests annually on each anniversary date through August 31, 2025. Read SEC document |
| May 25, 2021 Filed May 26, 2021 01:45 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | PurchaseCommon Stock | 1,000 | $5.29 | $5,290.00 |
DisclosureSEC source: 0001493152-21-012902 · ownership.xml · nonDerivative · entry 1 Amman Bradford K. · CIK 0001425339 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| March 12, 2021 Filed Mar 18, 2021 00:48 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option · Derivative | 100,000 | $7.50 Strike: $7.50 | $750,000.00 |
DisclosureSEC source: 0001493152-21-006291 · ownership.xml · derivative · entry 2 Amman Bradford K. · CIK 0001425339 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,001 Underlying: Common Stock · 100,000 shares Expires 2026-03-12 F1 · derivative.exercise_date: 100,000 stock options granted on March 12, 2021. One-fifth vested immediately and one-fifth vests annually on each anniversary date through March 12, 2025. Read SEC document |
| March 12, 2021 Filed Sep 3, 2021 01:27 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $7.50 Strike: $7.50 | $750,000.00 |
DisclosureSEC source: 0001493152-21-021915 · ownership.xml · derivative · entry 3 Amman Bradford K. · CIK 0001425339 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2026-03-12 F2 · derivative.exercise_date: 100,000 stock options granted on March 12, 2021. One-fifth vested immediately and one-fifth vests annually on each anniversary date through March 12, 2025. Read SEC document |
| December 24, 2020 Filed Dec 28, 2020 11:21 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | PurchaseCommon Stock | 1,000 | $7.38 | $7,380.00 |
DisclosureSEC source: 0001493152-20-024301 · ownership.xml · nonDerivative · entry 1 Amman Bradford K. · CIK 0001425339 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| November 18, 2019 Filed Sep 3, 2021 01:27 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 16,667 | $7.50 Strike: $7.50 | $125,002.50 |
DisclosureSEC source: 0001493152-21-021915 · ownership.xml · derivative · entry 4 Amman Bradford K. · CIK 0001425339 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires 2024-11-18 F3 · derivative.exercise_date: 16,667 stock options granted on November 18, 2019. One-fifth vested immediately and one-fifth vests annually on each anniversary date through November 18, 2023. Read SEC document |
| October 22, 2018 Filed Sep 3, 2021 01:27 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 83,334 | $7.50 Strike: $7.50 | $625,005.00 |
DisclosureSEC source: 0001493152-21-021915 · ownership.xml · derivative · entry 5 Amman Bradford K. · CIK 0001425339 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,334 Underlying: Common Stock · 83,334 shares Expires 2023-10-22 F4 · derivative.exercise_date: 83,334 stock options granted on October 22, 2018. One-fifth vested immediately and one-fifth vests annually on each anniversary date through October 22, 2022 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.